2017 Fiscal Year Final Research Report
Study on anti-EGFR antibody-resistant conquest of high DNA methylation type colorectal cancer
| Project/Area Number |
15H04307
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 雅信 東北大学, 加齢医学研究所, 准教授 (00447161)
高橋 信 東北大学, 大学病院, 講師 (20431570)
|
|---|
| Research Collaborator |
OUCHI Kota
OKITA Akira
KOBAYASHI Akihiro
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 大腸癌 / 高DNAメチル化型大腸癌 / 抗EGFR抗体薬 / 薬剤耐性 |
|---|
| Outline of Final Research Achievements |
The purposes of this study are to clarify a molecular mechanism determining anti-EGFR antibody treatment-resistant of high DNA methylation type colorectal cancer and to search for a method overcoming the resistance. As a result of comprehensive gene expression analysis, we determined that a specific subgroup correlated with effects of standard 1st-line treatment and of 3rd-line anti-EGFR antibody of the unresectable advanced or recurrent colorectal cancer and the second treatment. And as a result of comprehensive miRNA expression analysis, we identified that miR-193a-3p strongly correlated with BRAF mutation tumor, and that lower expression of miR-193a-3p associated with refractory of the anti-EGFR antibody. We are going to develop the study more in future.
|
| Free Research Field |
臨床腫瘍学
|
